Find Experts

Experts in Haematology
Julio A Aguirre-Ghiso Alberto Toso Yan Xiaojing William G. Finn Afua Mensah Scott A. Armstrong Richard Oscar Francis Jose Javier Bravo Cordero Steven J Burakoff Arek Z. Dudek Balkrishna Jahagirdar Dan J. Schneider Dr. David Saunders Bamlaku Enawgaw Dylan Zylla Muhammad Yasin Tipu Mr. Máté SZILASSY Mr. Roberto MARCOS Mr. Brian CONIBERE Mr. Julio FREYRE View More
Douglas W. Sborov

Professor
Department of Hematology
Huntsman Cancer Institute
United States of America

Professor Haematology
Biography

Dr. Sborov joined the faculty of the University of Utah – Huntsman Cancer Institute (HCI) in 2016 following completion his hematology, oncology, and bone marrow transplantation fellowships at The Ohio State University. During his training, he completed the NIH funded T32 Clinical Research Fellowship, obtained a Masters in Medical Science with a focus in translational research and immunology, and was a NCI Cancer Therapy Evaluation Program (CTEP) fellow. Dr. Sborov’s clinical practice primarily includes the treatment of patients with multiple myeloma and those undergoing bone marrow transplantation, but has also started a general hematology practice as part of the University of Utah community outreach program.

Research Intrest

iagnosis and Treatment of Patients with Multiple Myeloma Including High-dose Chemotherapy Plus Autologous Stem Cell Transplantation Bone Marrow Transplantation

List of Publications
Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA (2017). Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial.LID - 10.1002/cpt.644 [doi]. (Epub ahead of print) Clin Pharmacol Ther.
Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC (2017). A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma, 1-9.
Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC (2017). G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leuk Lymphoma, 1-5.c
Experts in United States of America
Jairaj K. Acharya John Belote Wayde Brown Aimée M. Dudley Jon P Mochel Rabaa M. Al-Rousan Chancellor, Renate Karen Lee Abt Lin Li Hui-Hsien Chou Hamed I. Aly Cory K. Adams Mark Ehrensberger Jose Buitrago Gerhard J. Barone Jacquelyne Adams Jon Calabria Shelley Cannady Susan B. Adams Stoica George Daniel E. Acuna Tal Amasay Jason R. Wiles Matthew H Andersen Brian Rothman View More